{"id":8477,"date":"2025-09-02T12:23:24","date_gmt":"2025-09-02T09:23:24","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8477"},"modified":"2025-09-02T12:23:24","modified_gmt":"2025-09-02T09:23:24","slug":"potcast-trial","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/potcast-trial\/","title":{"rendered":"POTCAST Trial\u00a0"},"content":{"rendered":"<div>POTCAST Trial<\/div>\n<div>Presented at ESC 2025 \u2013 Madrid &amp; published in NEJM at the same time.<\/div>\n<div>Source: Medical News | August 29, 2025<\/div>\n<div><\/div>\n<div><span> 1. Trial Design<\/span><\/div>\n<div><span> \u2022 POTCAST trial: 1200 patients with cardiovascular disease + ICD at high risk for ventricular arrhythmias.<\/span><\/div>\n<div><span> \u2022 Randomized to raise potassium (diet, supplements, MRAs) vs standard care.<\/span><\/div>\n<div><span> \u2022 Goal: increase plasma potassium to high-normal (4.5\u20135.0 mmol\/L).<\/span><\/div>\n<div><span> \u2022 Baseline potassium: 4.0 mmol\/L.<\/span><\/div>\n<div><span> 2. Main Results<\/span><\/div>\n<div><span> \u2022 Intervention raised potassium by +0.3 mmol\/L.<\/span><\/div>\n<div><span> \u2022 24% lower risk of composite endpoint (VT, ICD shocks\/pacing, HF\/arrhythmia hospitalization, or death).<\/span><\/div>\n<div><span> \u2022 Driven mainly by 25% reduction in ventricular tachycardia (122 vs 92 cases).<\/span><\/div>\n<div><span> \u2022 Benefit consistent across subgroups.<\/span><\/div>\n<div><span> 3. Safety<\/span><\/div>\n<div><span> \u2022 Slight rise in creatinine (+4 \u00b5mol\/L).<\/span><\/div>\n<div><span> \u2022 Hospitalizations: 17 intervention vs 12 control (not significant).<\/span><\/div>\n<div><span> \u2022 No excess hyperkalemia-related adverse events in patients with preserved kidney function.<\/span><\/div>\n<div><span> 4. Clinical Significance<\/span><\/div>\n<div><span> \u2022 First RCT to show that actively raising potassium reduces arrhythmias in ICD patients.<\/span><\/div>\n<div><span> \u2022 Comparable benefit to antiarrhythmic drugs, but with cheap, simple therapy.<\/span><\/div>\n<div><span> \u2022 Experts highlight importance of keeping potassium \u201cas high as possible within the safe range.\u201d<\/span><\/div>\n<div><span> 5. Broader Implications<\/span><\/div>\n<div><span> \u2022 Supports prior observational evidence: higher potassium \u2192 better CV outcomes + lower blood pressure.<\/span><\/div>\n<div><span> \u2022 Could extend to other CV patients, but US experts warn:<\/span><\/div>\n<div><span> \u2022 Trial excluded renal dysfunction.<\/span><\/div>\n<div><span> \u2022 Denmark\u2019s organized healthcare system may not reflect US practice.<\/span><\/div>\n<div><span> \u2022 In the US, may be most suitable for patients closely monitored in advanced HF\/ICD clinics.<\/span><\/div>\n<div><\/div>\n<div>\u2e3b<\/div>\n<div><\/div>\n<div>\ud83d\udc49 Conclusion:<\/div>\n<div>POTCAST provides high-level evidence that modestly increasing potassium to the high-normal range can significantly reduce ventricular arrhythmias and ICD shocks \u2014 a low-cost, safe strategy for many ICD patients, though careful monitoring is essential, especially outside trial settings.<\/div>\n<div><\/div>\n<div><a href=\"https:\/\/click.mail.medscape.com\/?qs=a275f6733bc75e6f13e470d4a0b643b30930be0fbc34fcff1ff1fce83c08bd39e6e9d9fd1a23ed25566454e0b6c6b4306039e70420ea8ae9fdfd840d281534f3\">https:\/\/click.mail.medscape.com\/?qs=a275f6733bc75e6f13e470d4a0b643b30930be0fbc34fcff1ff1fce83c08bd39e6e9d9fd1a23ed25566454e0b6c6b4306039e70420ea8ae9fdfd840d281534f3<\/a><\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>POTCAST Trial Presented at ESC 2025 \u2013 Madrid &amp; published in NEJM at the same time. Source: Medical News | August 29, 2025 1. Trial Design \u2022 POTCAST trial: 1200 patients with cardiovascular disease + ICD at high risk for ventricular arrhythmias. \u2022 Randomized to raise potassium (diet, supplements, MRAs) vs standard care. \u2022 Goal: [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8477","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8477"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8477\/revisions"}],"predecessor-version":[{"id":8478,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8477\/revisions\/8478"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}